In pediatrics (aged 6-<18-years) having moderate-to-severe plaque psoriasis, the dosing regimens of secukinumab were efficacious and well-tolerated. 

This study explored the efficacy and safety of 2 dosage regimens of secukinumab for the management of psoriasis in pediatrics.

In this randomized, phase-III, open-label, multicenter-study, two dosage regimens of secukinumab were used: (i) low dose: 75/75/150 mg and (ii) high dose: 75/150/300 mg. The dosage regimens were stratified and randomized by the severity of disease (severe, moderate) and weight (<25kg, 25-<50kg, ≥50kg).

Estimation of Psoriasis Area and Severity Index  (PASI) 75/90 and Investigator's Global Assessment (IGA) 0/1 was done.

Regarding PASI 75/90 and IGA0/1 responses, both high and low doses of secukinumab showed superiority to historical placebo at week 12. The estimated probability of positive therapeutic impact for secukinumab low dose or high dose in comparison with the historical placebo is 1 (i.e. 100%). For low and high doses, the IGA0/1 response-rates, PASI90 response-rates, and PASI75 response-rates at Week-12 are shown in Table 1:

Secukinumab showed high efficacy and favorable safety profile with both high and low dosing regimens up to 24 weeks in pediatrics suffering from psoriasis.